Figure 8. In vivo effects of edaravone and diethyl maleate (DEM) treatments of human umbilical cord mesenchymal stem cells (hUCMSCs) on serum markers and liver regeneration in an acute liver failure model induced by D-galactosamine/LPS (Gal/LPS).

(a,b) Edaravone treatment promoted proliferation and decreased apoptosis of transplanted hUCMSCs in the murine liver. (c,d) Edaravone further improved the ameliorative effects of hUCMSCs on serum aminotransferases level. (e,f) Edaravone further reduced the production of pro-inflammatory cytokines after liver failure. (g,h) Edaravone further promoted the host liver regeneration after liver failure. “*” “**” “***” mean significant changes (P < 0.05, 0.01, 0.001) between control and treatments, respectively; “#” “##” “###” mean significant changes (P < 0.05, 0.01, 0.001) between edaravone treatment group (10 μM or 20 μM) and LPS/H₂O₂ group, respectively; “@” means significant change (P < 0.05) between DEM-treated group and LPS/H₂O₂ group, respectively. GL, Gal/LPS.